Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.36 USD
+0.07 (5.43%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $1.35 -0.01 (-0.74%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
Price, Consensus and EPS Surprise
NKTR 1.36 +0.07(5.43%)
Will NKTR be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NKTR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NKTR
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
What Makes Nektar (NKTR) a New Buy Stock
NKTR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
Jazz Pharmaceuticals (JAZZ) Beats Q2 Earnings and Revenue Estimates
Other News for NKTR
Nektar Therapeutics (NKTR) Stock Surges Amid Market Fluctuations
Nektar assumed with a Buy at BTIG
Nektar rises 11% as BTIG initiates buy rating on autoimmune disorders asset
Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
Nektar Management to Present at Upcoming Investor Conferences